Media Library
Thomas Schall
President, Chief Executive Officer & Chairman
ChemoCentryx
Preview:
"We aim to change the current treatment paradigm with precision medicine. Avacopan, our highly specific small molecule, inhibits chemoattractant receptors with a precise mechanism of action"